Bio-Thera Solutions, Ltd. — Investor Relations & Filings
About Bio-Thera Solutions, Ltd.
Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 中国国际金融股份有限公司关于百奥泰生物制药股份有限公司部分募投项目子项目变更及金额调整的核查意见 | 2025-04-08 | Chinese | |
| 百奥泰 关于部分募投项目子项目变更及金额调整的公告 | 2025-04-08 | Chinese | |
| 百奥泰 2024年度会计师事务所履职情况评估报告 | 2025-04-08 | Chinese | |
| 百奥泰 第二届监事会第十九次会议决议的公告 | 2025-04-08 | Chinese | |
| 百奥泰 关于修订《公司章程》及部分公司治理制度的公告 | 2025-04-08 | Chinese | |
| 百奥泰生物制药股份有限公司对外担保管理制度 | 2025-04-08 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 39229884 | 中国国际金融股份有限公司关于百奥泰生物制药股份有限公司部分募投项目子项目变更及金额调整的核查意见 | 2025-04-08 | Chinese | ||
| 39229875 | 百奥泰 关于部分募投项目子项目变更及金额调整的公告 | 2025-04-08 | Chinese | ||
| 39229869 | 百奥泰 2024年度会计师事务所履职情况评估报告 | 2025-04-08 | Chinese | ||
| 39229866 | 百奥泰 第二届监事会第十九次会议决议的公告 | 2025-04-08 | Chinese | ||
| 39229860 | 百奥泰 关于修订《公司章程》及部分公司治理制度的公告 | 2025-04-08 | Chinese | ||
| 39229848 | 百奥泰生物制药股份有限公司对外担保管理制度 | 2025-04-08 | Chinese | ||
| 39229843 | 百奥泰 关于公司董事会换届选举的公告 | 2025-04-08 | Chinese | ||
| 39229832 | 中国国际金融股份有限公司关于百奥泰生物制药股份有限公司2024年度募集资金存放与使用情况的专项核查报告 | 2025-04-08 | Chinese | ||
| 39229826 | 百奥泰 第二届董事会第二十四次会议决议的公告 | 2025-04-08 | Chinese | ||
| 39229815 | 百奥泰生物制药股份有限公司关联交易管理制度 | 2025-04-08 | Chinese | ||
| 39229804 | 百奥泰 2024年度内部控制审计报告 | 2025-04-08 | Chinese | ||
| 39229762 | 百奥泰 2024年度营业收入扣除情况表的鉴证报告 | 2025-04-08 | Chinese | ||
| 39229719 | 百奥泰生物制药股份有限公司独立董事提名人声明与承诺（廖健） | 2025-04-08 | Chinese | ||
| 39229696 | 百奥泰 关于BAT1806（托珠单抗）业务发展最新情况的公告 | 2025-04-01 | Chinese | ||
| 39229687 | 百奥泰 自愿披露关于与Intas Pharmaceuticals Ltd.就BAT2506（戈利木单抗）注射液签署授权许可与商业化协议收到首付款的进展公告 | 2025-03-31 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Bio-Thera Solutions, Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58210/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58210 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58210 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58210 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58210}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bio-Thera Solutions, Ltd. (id: 58210)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.